Alchemab Is Bringing A New Meaning To Patient-Centered Care
British-Bostonian Biotech Is Working Backwards To Explain Disease Resilience
Alchemab Therapeutics sequences the antibodies of patients who prove especially resilient to hard-to-treat diseases to try and find therapeutic targets.
You may also be interested in...
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.
Sun Pharmaceuticals continues to dominate the Indian pharmaceutical space while its R&D costs are set to rise.